AU2015328163B2 - Multiple-variable IL-2 dose regimen for treating immune disorders - Google Patents

Multiple-variable IL-2 dose regimen for treating immune disorders Download PDF

Info

Publication number
AU2015328163B2
AU2015328163B2 AU2015328163A AU2015328163A AU2015328163B2 AU 2015328163 B2 AU2015328163 B2 AU 2015328163B2 AU 2015328163 A AU2015328163 A AU 2015328163A AU 2015328163 A AU2015328163 A AU 2015328163A AU 2015328163 B2 AU2015328163 B2 AU 2015328163B2
Authority
AU
Australia
Prior art keywords
tregs
subject
dose
biomarker
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015328163A
Other languages
English (en)
Other versions
AU2015328163A1 (en
Inventor
John Koreth
Jerome Ritz
Robert J. Soiffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2015328163A1 publication Critical patent/AU2015328163A1/en
Application granted granted Critical
Publication of AU2015328163B2 publication Critical patent/AU2015328163B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2015328163A 2014-10-09 2015-10-07 Multiple-variable IL-2 dose regimen for treating immune disorders Ceased AU2015328163B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061952P 2014-10-09 2014-10-09
US62/061,952 2014-10-09
PCT/US2015/054466 WO2016057651A1 (en) 2014-10-09 2015-10-07 Multiple-variable il-2 dose regimen for treating immune disorders

Publications (2)

Publication Number Publication Date
AU2015328163A1 AU2015328163A1 (en) 2017-05-04
AU2015328163B2 true AU2015328163B2 (en) 2020-10-15

Family

ID=55653714

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015328163A Ceased AU2015328163B2 (en) 2014-10-09 2015-10-07 Multiple-variable IL-2 dose regimen for treating immune disorders

Country Status (7)

Country Link
US (2) US10806773B2 (https=)
EP (1) EP3204119B1 (https=)
JP (1) JP6941561B2 (https=)
CN (2) CN107106876B (https=)
AU (1) AU2015328163B2 (https=)
CA (1) CA2963602A1 (https=)
WO (1) WO2016057651A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
SG11201908271WA (en) * 2017-03-14 2019-10-30 Juno Therapeutics Inc Methods for cryogenic storage
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022553370A (ja) * 2019-10-25 2022-12-22 ネオルーキン セラピューティクス，インコーポレイティド Ｉｌ－２受容体作動薬の投与方法
US20230414720A1 (en) * 2020-11-23 2023-12-28 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
EP4016078A1 (en) * 2020-12-18 2022-06-22 Rheinische Friedrich-Wilhelms-Universität Bonn Method useful in tolerance induction therapy and kits therefore
EP4422668A1 (en) * 2021-10-25 2024-09-04 Ellennbe GmbH Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases
EP4169524A1 (en) * 2021-10-25 2023-04-26 Ellennbe GmbH Immunomodulatory substance for use in a method for treatment and/or prevention of a disease
EP4426318A4 (en) * 2021-11-04 2025-11-19 Orca Biosystems Inc THERAPEUTIC COMPOSITIONS AND TRANSPLANTATION PROCESSES OF ALLOGENEIC HEMATOPOIETIC CELLS
WO2024084038A1 (en) * 2022-10-20 2024-04-25 Ellennbe Gmbh Platform technology for treatment of inflammatory, immunological and/or autoimmunological diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
WO2012123381A1 (en) * 2011-03-11 2012-09-20 Assistance Publique - Hôpitaux De Paris Use of low dose il-2 for treating autoimmune - related or inflammatory disorders
US20130071860A1 (en) * 2010-02-24 2013-03-21 Matthew B. Hale Methods for autoimmune disease diagnosis, prognosis, and treatment`

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33653A (en) 1861-11-05 Improvement in swivel hooks and rings
US548257A (en) 1895-10-22 Hay rake and loader
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60115528A (ja) 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
ATE205542T1 (de) 1992-03-04 2001-09-15 Univ California Vergleichende genomhybridisierung
US5965362A (en) 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
JP4137996B2 (ja) 1992-05-06 2008-08-20 ジェン−プローブ・インコーポレイテッド 核酸配列増幅方法，組成物及びキット
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
DE4344726C2 (de) 1993-12-27 1997-09-25 Deutsches Krebsforsch Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6045788A (en) 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
CA2255430C (en) 1998-12-10 2003-08-26 P. Wedge Co. Ltd. A swivel device for a windcone tower assembly
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
WO2007136518A2 (en) 2006-05-17 2007-11-29 Torrey Pines Institute For Molecular Studies Treatment of autoimmune disorders
WO2010101870A1 (en) 2009-03-03 2010-09-10 St. Jude Children's Research Hospital Compositions and methods for generating interleukin-35-induced regulatory t cells
WO2011139738A2 (en) 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
US20130071860A1 (en) * 2010-02-24 2013-03-21 Matthew B. Hale Methods for autoimmune disease diagnosis, prognosis, and treatment`
WO2012123381A1 (en) * 2011-03-11 2012-09-20 Assistance Publique - Hôpitaux De Paris Use of low dose il-2 for treating autoimmune - related or inflammatory disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KORETH JOHN ET AL, "Tregs, HSCT, and acute GVHD: up close and personal.", BLOOD 05 SEP 2013, (2013-09-05), vol. 122, no. 10, ISSN 1528-0020, pages 1690 - 1691 *
MATSUOKA KEN-ICHI ET AL, "Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease", SCIENCE TRANSLATIONAL MEDICINE, (2013-04), vol. 5, no. 179 *
SAADOUN ET AL, "Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis", N Engl J Med. 2011 Dec 1;365(22):2067-77 *

Also Published As

Publication number Publication date
EP3204119A1 (en) 2017-08-16
JP6941561B2 (ja) 2021-09-29
US20210077580A1 (en) 2021-03-18
AU2015328163A1 (en) 2017-05-04
CN113230384A (zh) 2021-08-10
CN107106876B (zh) 2021-06-11
JP2018500276A (ja) 2018-01-11
US10806773B2 (en) 2020-10-20
EP3204119B1 (en) 2021-06-09
EP3204119A4 (en) 2018-06-20
WO2016057651A1 (en) 2016-04-14
US20170348391A1 (en) 2017-12-07
CN107106876A (zh) 2017-08-29
CA2963602A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
AU2015328163B2 (en) Multiple-variable IL-2 dose regimen for treating immune disorders
US11944647B2 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
EP3886875B1 (en) Methods for treatment using adoptive cell therapy
CA2964363A1 (en) Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators
US20240110230A1 (en) Biomarkers for cancer treatment
CN110945030A (zh) 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
US20220298222A1 (en) Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
WO2023178290A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
Lemarquis et al. Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage
Lupo et al. TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma
Obradovic et al. Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models
US20240417802A1 (en) Immunotherapeutic methods for treating cancer
Zhao et al. Intragraft memory-like CD127hiCD4+ Foxp3+ Tregs maintain transplant tolerance
AU2023204881A1 (en) Novel personal neoantigen vaccines and markers
Lee The immunological profile of renal cell carcinoma patients
Banham et al. A Phase 2 Experimental Medicine Randomised Placebo Controlled Trial of Belimumab in Kidney Transplantation (BEL114424)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)